Latest Breaking News On - ஓலகீ உயிர் சேவைகள் - Page 6 : comparemela.com

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomSouth africaMacau generalSouth africanBen matoneJeff richardsonKaneka eurogentecJ joseph kimWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyUs department of defense doPlumbline life sciences

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.

Ben matoneJeff richardsonKaneka eurogentecKwadwoa koramWalter reed army institute of researchUs department of defenseNational cancer instituteNoguchi memorial institute for medical researchNational institute of allergyPlumbline life sciencesMelinda gates foundationCoalition for epidemic preparedness innovationsInternational vaccine instituteDefense consortiumParker institute for cancer immunotherapyNuclear defense

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Share this article Share this article PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 is also the first vaccine candidate for Lassa fever to enter human trials.

Greater accraBen matoneJeff richardsonKaneka eurogentecMelanie savilleJ joseph kimKwadwoa koramWalter reed army institute of researchUs department of defenseNational cancer instituteNoguchi memorial institute for medical researchNational institute of allergyNoguchi medical centerPlumbline life sciencesMelinda gates foundationCoalition for epidemic preparedness innovations

Bioterrorism Agent Market Breaking New Grounds and Touch New Level in upcoming year by Evogen, Inc , Altimmune, Bavarian Nordic, Emergent BioSolutions Inc – KSU

a2zJanuary 29, 2021 93 Bioterrorism Agent Market research report is the new statistical data source added by A2Z Market Research. It uses several approaches for analyzing the data of target market such as primary and secondary research methodologies. It includes investigations based on historical records, current statistics, and futuristic developments. The global Bioterrorism Agent Market size is expected to Expand at Significant CAGR of +4% during forecast period (2021-2027). Bioterrorism is defined as the deliberate use of pathogenic microorganism strains involving bacteria, viruses and the toxin produced by them in order to spread the life- threatening diseases with an aim to attack a large population size. Increasing technological advancement, introduction of bioengineering field, advancement in genetic engineering technologies has paved the way for terrorist to use biological weapons for harming the population.

Republic ofRoger smithElusys therapeutics incEmergent biosolutions incAlnylam pharmaceuticals incZ market researchOur research analystLanzhou institute of biological products co ltdBiofactura incEvogen incBioterrorism agent marketSample copyIndustry trendBavarian nordicCleveland biolabsOlogy bioservices

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

Dr. J. Joseph Kim, President and Chief Executive Officer of INOVIO, said, INOVIO s partnership with Advaccine enables us to leverage their deep expertise, capabilities and network across the region – making it possible to rapidly produce and if and when approved, distribute our vaccine candidate to more people across Greater China. This agreement also provides INOVIO with an Asian manufacturing partner with a near-term focus on INO-4800 and a long-term manufacturing resource potentially for other INOVIO products. We are grateful for Advaccine joining our global manufacturing coalition as a dedicated resource for Greater China and look forward to our continued partnership in the fight against COVID-19.

Hong kongBin wangSouth koreaMacau generalBen matonePablo tebasJeff richardsonKaneka eurogentecJ joseph kimWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyPlumbline life sciencesLaval universityMelinda gates foundation